Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 11:16:1809-1813.
doi: 10.2147/RMHP.S426869. eCollection 2023.

Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review

Abduelmula R Abduelkarem  1   2 , Adnane Guella  3 , Amar M Hamrouni  4 , Mohammed M Hassanein  1 , Ahmed Nasr  5 , Owais Rana  6
Affiliations
Review

Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review

Abduelmula R Abduelkarem et al. Risk Manag Healthc Policy. .

Abstract

Chronic kidney disease (CKD) and hemodialysis (HD) patients have a high incidence of bone disease and increased fracture risk, making effective management of their bone health a clinical challenge. Denosumab, a human monoclonal antibody, has been investigated as a therapeutic option in this patient population. In this review, we summarize the current evidence on the efficacy and safety of denosumab in CKD and HD patients. A comprehensive search of the relevant literature was conducted, including randomized controlled trials, observational studies, and meta-analyses. The findings suggest that denosumab reduces the risk of fractures and improves bone mineral density in all stages of CKD. The results of this review support the use of denosumab as a promising option for managing bone disease in CKD and HD patients.

Keywords: bone disease; chronic kidney disease; denosumab; fracture risk reduction; hemodialysis.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest associated with the material presented in this paper.

References

    1. Bover J, Bailone L, López-Báez V, et al. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017;30(5):677–687. doi: 10.1007/s40620-017-0404-z - DOI - PubMed
    1. Ginsberg C, Ix JH. Diagnosis and management of osteoporosis in advanced kidney disease: a review. Am J Kidney Dis. 2022;79(3):427–436. doi: 10.1053/j.ajkd.2021.06.031 - DOI - PubMed
    1. Lehmann G, Wolf G. Medikamentöse Therapie von Knochenstoffwechselstörungen bei CKD-MBD (“chronic kidney disease – mineral bone disorder“) unter besonderer Berücksichtigung antiresorptiver Wirkstoffe [Pharmaceutical therapy of bone metabolism disorders in chronic kidney disease mineral bone disorder (CKD-MBD) with special respect to antiresorptive substances]. Z Rheumatol. 2014;73(4):329–334. German. doi: 10.1007/s00393-013-1287-6 - DOI - PubMed
    1. Liu WC, Yen J-F, Lang C-L, et al. Bisphosphonates in CKD patients with low bone mineral density. Sci World J. 2013;2013:837573. doi: 10.1155/2013/837573 - DOI - PMC - PubMed
    1. Moe SM. Renal Osteodystrophy or Kidney-Induced Osteoporosis? Curr Osteoporos Rep. 2017;15(3):194–197. doi: 10.1007/s11914-017-0364-1 - DOI - PMC - PubMed